Yanfang Tao
-
- Acute Myeloid Leukemia Research 3
-
- Protein Degradation and Inhibitors 7
- Ubiquitin and proteasome pathways 7
- Histone Deacetylase Inhibitors Research 6
- Cancer-related gene regulation 5
- Epigenetics and DNA Methylation 3
- Renal and related cancers 2
-
- CAR-T cell therapy research 2
- Co-authors
- Jian PanZhi-Heng LiXing FengJun LuYanhong LiLixiao XuFang FangXiaolu Li
- Journals
- Biochemical and Biophysical Research Communications (1 paper)International Journal of Molecular Sciences (1 paper)International Journal of Hydrogen Energy (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Yanfang Tao
23 papers receiving 343 citations
Peers
Comparison fields: 5 of 69
- Hematology 53
- Molecular Biology 251
- Cancer Research 51
- Oncology 85
- Cell Biology 30
Countries citing papers authored by Yanfang Tao
This map shows the geographic impact of Yanfang Tao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanfang Tao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanfang Tao more than expected).
Fields of papers citing papers by Yanfang Tao
This network shows the impact of papers produced by Yanfang Tao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanfang Tao. The network helps show where Yanfang Tao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yanfang Tao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 5 | |
| 6 | 2023 | 17 | |
| 7 | 2022 | 12 | |
| 8 | 2021 | 23 | |
| 9 | 2021 | 50 | |
| 10 | 2020 | 6 | |
| 11 | 2017 | 17 | |
| 12 | 2017 | 33 | |
| 13 | 2017 | 30 | |
| 14 | A novel sphingosine kinase 1 inhibitor (SKI-5C) induces cell death of Wilms' tumor cells in vitro and in vivo. | 2016 | 11 |
| 15 | 2015 | 7 | |
| 16 | 2015 | 15 | |
| 17 | 2015 | 5 | |
| 18 | 2015 | 17 | |
| 19 | 2014 | 24 | |
| 20 | 2012 | 40 |
About Yanfang Tao
Yanfang Tao is a scholar working on Hematology, Molecular Biology and Urology, having authored 23 papers that have together received 347 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (7 papers), Ubiquitin and proteasome pathways (7 papers), Histone Deacetylase Inhibitors Research (6 papers), Cancer-related gene regulation (5 papers), Acute Myeloid Leukemia Research (3 papers), Epigenetics and DNA Methylation (3 papers), CAR-T cell therapy research (2 papers) and Renal and related cancers (2 papers). The work is most often cited by research in Hematology (53 citations), Molecular Biology (251 citations) and Cancer Research (51 citations). Yanfang Tao has collaborated with scholars based in China and United States. Frequent co-authors include Jian Pan, Zhi-Heng Li, Xing Feng, Jun Lu, Yanhong Li, Lixiao Xu, Fang Fang, Xiaolu Li, Jianwen Wang and Yanling Chen. Their work appears in journals such as Biochemical and Biophysical Research Communications, International Journal of Molecular Sciences and International Journal of Hydrogen Energy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.